GOTIC-018: Phase I, open-label, multicenter study to assess the safety of pre- and co-administration of ONO-4538 (nivolumab) with concurrent chemoradiation (CCRT) in patients (pts) with locally advanced cervical carcinoma (LACvCa).

Authors

Akira Yabuno

Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan

Akira Yabuno , Kazuto Nakamura , Toyomi Satoh , Hiroyuki Fujiwara , Akira Kurosaki , Soichi Yamashita , Toshihiro Misumi , Shin-ei Noda , Kosei Hasegawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Primary safety and short-term efficacy results for cohort E.

First Author: Takako Yoshii

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.

First Author: Manuel Rodrigues

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.

First Author: Masafumi Ikeda

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

First Author: Igor Tsaur